You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 7 | Journal for ImmunoTherapy of Cancer

Fig. 7

From: Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning

Fig. 7

Administration of MPL or CpG enhances antitumor immunity in irradiated mice. Mice bearing subcutaneous B16F10 tumors established for 8 days received 5Gy TBI. One day after TBI, mice received an ACT treatment comprised of the adoptive transfer of 5e5 cultured pmel-1 T cells, fowlpox hgp100 vaccination and hIL-2 or were left untreated. The next day, mice received either (a) 5 μg MPL (i.v.) or (b) 10 μg of CpG (i.t.), daily for 4 days, or left untreated. Data shown (mean ± SEM, 5–10 mice per group) are representative of 2 independent experiments. For MPL treatment: 5Gy PFI vs. NT (*P < 0.05) or 5Gy MPL post-PFI (*P < 0.05), ANOVA. For CpG treatment: 5Gy PFI vs. NT (**P < 0.01) or 5Gy CpG post-PFI (*P < 0.05), ANOVA

Back to article page